Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose

Clinical Drug Investigation

Volumn 34, Issue 1, 2014, Pages 1-7

  Han, Ying ^a   Shi, Jun Ping ^b   Ma, An Lin ^c   Xu, Yun ^d   Ding, Xiao Dong ^e   Fan, Jian Gao ^e  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^c CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^d THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^e XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; BICYCLOL; BIPHENYL DERIVATIVE; METFORMIN; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CONTROLLED STUDY; DIARRHEA; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG EFFICACY; DRUG SAFETY; FATTY LIVER; HEPATITIS; HUMAN; IMPAIRED FASTING GLUCOSE; LIFESTYLE MODIFICATION; LIVER BIOPSY; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; WAIST HIP RATIO; BLOOD; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; FEMALE; HYPOGLYCEMIA; LIVER; MALE; MULTICENTER STUDY; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ALANINE TRANSAMINASE; BIPHENYL COMPOUNDS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIA; LIVER; MALE; METFORMIN; NON-ALCOHOLIC FATTY LIVER DISEASE; VITAMIN E;

EID: 84891875342     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0136-3     Document Type: Article

References (27)

1. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274-85.
2. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005-23.
3. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675-85.
4. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2004;19(5):537-44. (Pubitemid 38387180)
5. Nair S, Diehl AM, Wiseman M, Farr GH Jr, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther. 2004;20(1):23-8. (Pubitemid 38938715)
6. Liu GT. Bicyclol: a novel drug for treating chronic viral hepatitis B and C. Med Chem. 2009;5(1):29-43.
7. Pan SY, Dong H, Yu ZL, Zhao XY, Xiang CJ, Wang H, et al. Bicyclol, a synthetic dibenzocyclooctadiene derivative, decreases hepatic lipids but increases serum triglyceride level in normal and hypercholesterolaemic mice. J Pharm Pharmacol. 2007;59(12):1657-62. (Pubitemid 350221810)
8. Su HL, Zhu YX, Gao ZJ, Dong XY, Zhu JY, Lei WR, et al. Efficacy comparison between bicyclol and polyene phosphatidylcholine treatments for the patients with nonalcoholic fatty liver disease. Chin J Hepatol. 2011;19(7):552-3.
9. Xie W, Shi G, Zhang H, Zhao G, Yu Z, Lang Z, et al. A randomized, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol. Hepatol Int. 2012;6(2):441-8.
10. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142(1):37-46.
11. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007;297(8):842-57. (Pubitemid 46333949)
12. Farrell GC, Chitturi S, Lau GK, Sollano JD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol. 2007;22(6):775-7. (Pubitemid 46911045)
13. Cao HX, Fan JG. Editorial: fatty liver disease: a growing public health problem worldwide. J Dig Dis. 2011;12(1):1-2.
14. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010;52(2):774-88.
15. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341-50.
16. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51(6):1972-8.
17. Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci. 2005;330(6):326-35. (Pubitemid 41831904)
18. Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol. 2008;14(2):185-92. (Pubitemid 351314297)
19. Nakanishi N, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care. 2004;27(6):1427-32. (Pubitemid 38679993)
20. Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28(1):27-38.
21. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865-73. (Pubitemid 46489550)
22. Fracanzani AL, Burdick L, Raselli S, Pedotti P, Grigore L, Santorelli G, et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med. 2008;121(1):72-8.
23. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43(2 Suppl 1):S99-112.
24. Fan JG, Jia JD, Li YM, Wang BY, Lu LG, Shi JP, et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18:163-166). J Dig Dis. 2011;12(1):38-44.
25. Liu GT, Li Y, Wei HL, Zhang H, Xu JY, Yu LH. Mechanism of protective action of bicyclol against CCl-induced liver injury in mice. Liver Int. 2005;25(4):872-9. (Pubitemid 41038669)
26. Wang H, Li Y. Protective effect of bicyclol on acute hepatic failure induced by lipopolysaccharide and d-galactosamine in mice. Eur J Pharmacol. 2006;534(1-3):194-201. (Pubitemid 43384201)
27. Zhao J, Chen H, Li Y. Protective effect of bicyclol on acute alcohol-induced liver injury in mice. Eur J Pharmacol. 2008;586(1-3):322-31.